Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan
Authors
Keywords
-
Journal
PLoS One
Volume 8, Issue 9, Pages e74345
Publisher
Public Library of Science (PLoS)
Online
2013-09-13
DOI
10.1371/journal.pone.0074345
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Markers of Response for the Antiangiogenic Agent Bevacizumab
- (2013) Diether Lambrechts et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO)
- (2012) Miguel J. Gil et al. ANTI-CANCER DRUGS
- Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma
- (2012) Yun Cao et al. CANCER
- VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
- (2012) Kan V. Lu et al. CANCER CELL
- Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria
- (2012) J. G. Perez-Larraya et al. NEURO-ONCOLOGY
- Circulating Endothelial Cells and Microparticles as Prognostic Markers in Advanced Non-Small Cell Lung Cancer
- (2012) Tania Fleitas et al. PLoS One
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration
- (2012) Douglas G. Altman et al. PLOS MEDICINE
- Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab †
- (2011) D. Malka et al. ANNALS OF ONCOLOGY
- The TGF-β co-receptor, CD109, promotes internalization and degradation of TGF-β receptors
- (2011) Albane A. Bizet et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression
- (2011) M. Franco et al. BLOOD
- Bevacizumab and daily temozolomide for recurrent glioblastoma
- (2011) Annick Desjardins et al. CANCER
- Glioblastoma Angiogenesis and Tumor Cell Invasiveness Are Differentially Regulated by 8 Integrin
- (2011) J. H. Tchaicha et al. CANCER RESEARCH
- Advances in MRI Assessment of Gliomas and Response to Anti-VEGF Therapy
- (2011) Whitney B. Pope et al. Current Neurology and Neuroscience Reports
- Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab
- (2011) Philip Weißhardt et al. HISTOCHEMISTRY AND CELL BIOLOGY
- Circulating endothelial cells as biomarkers for patients receiving bevacizumab
- (2011) Francesco Bertolini et al. LANCET ONCOLOGY
- Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma
- (2011) Olivier Keunen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy
- (2010) F.- C. Bidard et al. ANNALS OF ONCOLOGY
- Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients
- (2010) M. Ronzoni et al. ANNALS OF ONCOLOGY
- The predictive and prognostic value of circulating endothelial cells in advanced colorectal cancer patients receiving first-line chemotherapy and bevacizumab
- (2010) L. H. J. Simkens et al. ANNALS OF ONCOLOGY
- Bevacizumab for Malignant Gliomas
- (2010) Fabio M. Iwamoto et al. ARCHIVES OF NEUROLOGY
- Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer
- (2010) Satoshi Matsusaka et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Application of polychromatic flow cytometry to identify novel subsets of circulating cells with angiogenic potential
- (2010) Myka L. Estes et al. CYTOMETRY PART A
- Circulating perivascular progenitors: A target of PDGFR inhibition
- (2010) Patrizia Mancuso et al. INTERNATIONAL JOURNAL OF CANCER
- Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
- (2010) James R. Perry et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- (2010) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiographic patterns of relapse in glioblastoma
- (2010) Marc C. Chamberlain JOURNAL OF NEURO-ONCOLOGY
- Biomarkers to predict the clinical efficacy of bevacizumab in cancer
- (2010) Adrian M Jubb et al. LANCET ONCOLOGY
- Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab
- (2009) A. Calleri et al. CLINICAL CANCER RESEARCH
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating endothelial progenitor cells in malignant gliomas
- (2009) Neysan Rafat et al. JOURNAL OF NEUROSURGERY
- Validation of a Standardized Method for Enumerating Circulating Endothelial Cells and Progenitors: Flow Cytometry and Molecular and Ultrastructural Analyses
- (2008) P. Mancuso et al. CLINICAL CANCER RESEARCH
- VEGF and TGF-β are required for the maintenance of the choroid plexus and ependyma
- (2008) Arindel S.R. Maharaj et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A role for VEGF as a negative regulator of pericyte function and vessel maturation
- (2008) Joshua I. Greenberg et al. NATURE
- Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
- (2008) A. D. Norden et al. NEUROLOGY
- Hematopoietic Stem Cell–Derived Pericytic Cells in Brain Tumor Angio-Architecture
- (2008) Simon R. Bababeygy et al. STEM CELLS AND DEVELOPMENT
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search